DBV Technologies | DBVT - Trade Creditors

Stock Price
19.65
Daily Change
-0.19 -0.96%
Monthly
-4.66%
Yearly
77.03%
Q2 Forecast
19.19

DBV Technologies reported $39.82M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amarin USD 48.15M 2.8M Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
DBV Technologies USD 39.82M 972K Sep/2025
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Galectin Therapeutics USD 3.7M 99K Jun/2024
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026